Sanofi India Ltd (SANOFI) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sanofi India Ltd on NSE and BSE, with an AI summary of each filing.
Kindly refer the attachment
Dividend · 30 Oct 2026, 3:26 am
Sanofi India Declares Rs. 75 Interim Dividend with TDS Guidelines Sanofi India declared an interim dividend of Rs. 75 per equity share (face value Rs. 10) for FY26 on 29th Oct'26. The record date is set for 5th Nov'26. Resident individuals face a 10% TDS with valid PAN, while amounts up to Rs. 10,000 or valid Form 121 submissions are exempt; invalid/missing PAN incurs 20%. Non-resident payouts attract a 20% TDS plus cess/surcharge, subject to applicable DTAA provisions. Required tax exemption declarations must be submitted to the RTA by 5th Nov'26, 5:00 PM IST.
Kindly refer the attachment
Dividend · 30 Oct 2026, 12:15 am
Sanofi India Q3'26 Results: Net Profit Surges 53.6% YoY; ₹75 Interim Dividend Declared Sanofi India reported a 3.4% YoY rise in revenue from operations to ₹4,917 million for Q3 ended 30th Sep'26. Net profit surged 53.6% YoY to ₹1,167 million, aided by an 8% drop in operating expenses, favorable mix, and a low base with past exceptional costs. PBT before exceptionals grew 21.7% YoY to ₹1,577 million. Performance was led by 9% growth in the diabetes insulin portfolio (55% market share). The board declared an interim dividend of ₹75 per share, with record date fixed as 5th Nov'26.
Kindly refer the attachment
Dividend · 30 Oct 2026, 12:13 am
Sanofi India Reports Robust Q3'26 Profit Growth and Declares ₹75 Interim Dividend Sanofi India posted a 3.4% YoY rise in Q3'26 revenue from operations to ₹4,917 million, while net profit surged 53.6% YoY to ₹1,167 million, driven by gross margin expansion, favorable product mix, and an 8% drop in operating expenses. Profit before tax rose 22% YoY to ₹1,577 million. Performance was supported by 9% growth in the insulin portfolio (55% market share) and an 85% surge in public sector business. The board declared an interim dividend of ₹75 per share with a record date of 5th Nov'26.
Kindly refer the attachment
Dividend · 30 Oct 2026, 12:09 am
Sanofi India Q3'26 Results: Net Profit Surges 54% YoY; ₹75 Interim Dividend Declared Sanofi India reported a 53.6% YoY jump in net profit to ₹1,167 million for Q3'26, driven by a 3.4% YoY rise in revenue from operations to ₹4,917 million and an 8% drop in operating expenses. Profit before tax and exceptional items rose 21.7% YoY to ₹1,577 million, expanding PBT margins to 32.1%. Performance was led by 9% growth in its diabetes injectable portfolio (55% market share). The board declared an interim dividend of ₹75 per share, setting the record date as 5th Nov'26.
Kindly refer the attachment
Press Release · 30 Oct 2026, 12:06 am
Sanofi India Reports Robust Q3'26 Profit Growth and Declares ₹75 Interim Dividend Sanofi India reported a 3.4% YoY rise in revenue from operations to ₹4,917 million for the quarter ended 30th Sep'26, while net profit surged 53.6% YoY to ₹1,167 million. Profit before tax and exceptional items rose 21.7% YoY to ₹1,577 million, supported by an 8% reduction in operating expenses and a 9% growth in the insulin portfolio (55% market share). The board declared an interim dividend of ₹75 per equity share (face value ₹10) with the record date set for 5th Nov'26.
Kindly refer the attachment
Outcome · 30 Oct 2026, 12:02 am
Sanofi India Q3'26 Results: Net Profit Surges 54% YoY; ₹75 Interim Dividend Declared Sanofi India reported a 3.4% YoY rise in Q3'26 revenue from operations to ₹4,917 million, driven by 9% growth in its diabetes injectable portfolio, which holds a 55% market share. Net profit jumped 53.6% YoY to ₹1,167 million, supported by an 8% reduction in operating expenses and provision reversals. Profit before tax margin expanded to 34% from 29% in Q3'25. Additionally, the Board declared an interim dividend of ₹75 per equity share (face value ₹10), fixing the record date as 5th Nov'26.
Sanofi India Limited has submitted to the Exchange, the unaudited financial results for the quarter and nine months ended 30th September 2026.
Outcome · 29 Oct 2026, 11:58 pm
Sanofi India Reports Robust Q3'26 PAT Growth and Declares Interim Dividend Sanofi India posted a 3.4% YoY rise in Q3'26 revenue from operations to ₹4,917 million, with domestic sales up 2% and diabetes insulin growing 9% YoY. Profit Before Tax surged 54.2% YoY to ₹1,577 million, supported by an 8% drop in operating expenses and favorable mix. Net profit rose 53.6% YoY to ₹1,167 million, with EPS reaching ₹50.67 versus ₹32.99 in Q3'25. The board declared an interim dividend of ₹75 per equity share, setting the record date as 5th Nov'26.
Kindly refer the attachment
Financial Result · 29 Oct 2026, 11:56 pm
Sanofi India Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Million) ■ Revenue: 4,917 (+3.4% YoY | +12.3% QoQ) ■ EBITDA: 1,612 (+20.1% YoY | +39.8% QoQ) ■ EBITDA Margin (%): 32.8 (+456 bps YoY | +644 bps QoQ) ■ PAT: 1,167 (+53.6% YoY | +39.8% QoQ) ■ EPS (INR): 50.7 (+53.6% YoY | +39.7% QoQ)
Board Meeting Intimation for Consideration and Approval of the Unaudited Financial Results for the Quarter and Nine Months ended 30th September 2026; and Declaration and Approval of Interim Dividend, if any, for the Financial Year 2026.
Intimation · 29 Oct 2026, 5:30 am
Sanofi India Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Dividend.
Intimation · 29 Oct 2026, 5:30 am
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 29 Oct 2026, 5:30 am
Sanofi India Board to Consider Q3CY26 Results and Interim Dividend on 29th Oct'26 Sanofi India's Board of Directors is scheduled to meet on 29th Oct'26 to consider and approve the unaudited financial results for the quarter and nine months ended 30th Sep'26. The board will also consider and declare an interim dividend, if any, for FY26. Consequently, the trading window for dealing in company securities remains closed from 1st Oct'26 until 48 hours following the announcement of the financial results to stock exchanges.
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(iii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Others (Uncategorized) · 07 Oct 2026, 9:25 pm
Sanofi Healthcare India Acquires 15.20% Stake in Sanofi India via Inter-Se Transfer Sanofi Healthcare India Private Limited acquired 3,500,000 equity shares (15.20% stake) of Sanofi India Limited from promoter Hoechst GmbH on 24th Sep'26 at Rs. 3,052.00 per share via a block deal. The inter-se transaction reduced Hoechst GmbH’s stake from 60.38% (13,904,722 shares) to 45.18% (10,404,722 shares), while total promoter and promoter group holding remained unchanged at 60.40% (13,909,587 shares). The acquisition qualified for an open offer exemption under Regulation 10(1)(a)(iii) of SEBI SAST Regulations, with the transaction price comfortably below the 60-day VWAP limit of Rs. 3,228.06 per share.
Kindly refer the attachment.
Others (Uncategorized) · 29 Sept 2026, 4:28 pm
Sanofi India Receives Rs 16.40 Cr GST Show Cause Notice Sanofi India received a Show Cause Notice dated 28th Sep'26 from Gujarat GST authorities proposing an aggregate demand of Rs 16,40,07,641 (tax, interest, and penalties) for FY'23. Key allegations include discrepancies between E-Way Bills and GSTR-1, GSTR-9C turnover reconciliations, short reversal of input tax credit (ITC), and ineligible ITC claims. The company is examining the notice with tax advisors to submit a reply within prescribed timelines and does not envisage any material adverse impact on financials or operations.
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanofi Healthcare India Pvt Ltd
Others (Uncategorized) · 28 Sept 2026, 9:13 pm
Sanofi Healthcare Acquires 15.20% Stake in Sanofi India via Inter-Se Transfer Sanofi Healthcare India Private Limited acquired 3,500,000 equity shares (15.20% stake) of Sanofi India Limited from promoter Hoechst GmbH on 24th Sep'26 at Rs 3,052 per share via an on-market block deal. Following this exempted inter-se promoter transfer under SEBI SAST Regulation 10(1)(a)(iii), Hoechst GmbH’s shareholding decreased from 60.38% (13,904,722 shares) to 45.18% (10,404,722 shares), while Sanofi Healthcare India’s stake rose to 15.20%. The aggregate holding of the promoter and promoter group remains unchanged at 60.40%.
Disclosure received by the Company on 25th September 2026 under Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Sanofi Healthcare India Private Limited, ....
Others (Uncategorized) · 28 Sept 2026, 6:59 pm
Sanofi Healthcare India Acquires 15.20% Stake in Sanofi India via Inter-Se Transfer Sanofi Healthcare India Private Limited, a promoter group entity, acquired 3,500,000 equity shares (15.20% stake) of Sanofi India Limited on 24th Sep'26 for INR 1,068.20 crore. The transaction was executed via an inter-se promoter transfer from Hoechst GmbH through a block deal mechanism on the NSE, raising Sanofi Healthcare India's holding from nil to 15.20%.
Disclosure received by the Company on 25th September 2026 under Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Hoechst GmbH, a promoter of the Company
Others (Uncategorized) · 28 Sept 2026, 6:55 pm
Sanofi India Promoter Hoechst GmbH Executes Block Deal Inter-Se Stake Transfer Sanofi India promoter Hoechst GmbH sold 3,500,000 equity shares valued at INR 10,68,20,00,000 via a block deal on the NSE on 24th Sep'26. The transaction represents an inter-se transfer to fellow promoter group entity Sanofi Healthcare India Private Limited. Following the transaction, Hoechst GmbH's shareholding in Sanofi India decreased from 13,904,722 shares (60.38%) to 10,404,722 shares (45.18%). The company received the statutory PIT disclosure on 25th Sep'26 and notified the exchanges on 28th Sep'26.
Kindly refer the attachment
Others (Uncategorized) · 26 Sept 2026, 4:01 am
Sanofi India Receives GST Show Cause Notice of ₹23.74 Crore Sanofi India Limited received a Show Cause Notice on 25th Sep'26 from the Commercial Tax Officer, Bengaluru, under Section 73 of the Karnataka GST Act, 2017. The authority alleged excess Input Tax Credit claims for FY 2022-23 (Apr'22 to Mar'23), proposing a tax liability of ₹14.43 crore and interest of ₹9.31 crore, aggregating to ₹23.74 crore. The company is evaluating the notice with tax advisors to file a response and does not envisage any adverse impact on its financials or operations.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hoechst GmbH & PACs
Acquisition/ Disposal of Shares · 25 Sept 2026, 8:23 pm
Sanofi Promoter Entity Executes 15.20% Stake Inter-Se Transfer in Sanofi India Promoter entity Hoechst GmbH sold 3,500,000 equity shares (15.20% stake) of Sanofi India Limited to Sanofi Healthcare India Private Limited via an on-market inter-se transfer block deal on 24th Sep'26. Post-transaction, Hoechst GmbH's direct holding decreased from 60.38% (13,904,722 shares) to 45.18% (10,404,722 shares), while acquirer Sanofi Healthcare India's stake rose to 15.20%. Aggregate promoter and PAC shareholding remained unchanged at 60.40% (13,909,587 shares) of the total equity share capital comprising 23,030,622 shares.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanofi Healthcare India Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 25 Sept 2026, 8:21 pm
Sanofi Healthcare India Acquires 15.20% Stake in Sanofi India via Inter-Se Transfer Sanofi Healthcare India Private Limited acquired 3,500,000 equity shares (15.20% stake) of Sanofi India Limited from promoter Hoechst GmbH on 24th Sep'26. The transaction was executed via an inter-se promoter group transfer through a stock exchange block deal mechanism under SEBI SAST Regulation 10(1)(a)(iii) exemption. Post-transaction, Hoechst GmbH's holding decreased to 45.18% (10,404,722 shares), while Sanofi Healthcare India's stake rose to 15.20%. Aggregate promoter and PAC shareholding in Sanofi India remains unchanged at 60.40% (13,909,587 shares). Total equity capital stands at 23,030,622 shares.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanofi Healthcare India Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 25 Sept 2026, 7:07 pm
Sanofi Healthcare India Acquires 15.20% Stake in Sanofi India via Inter-Se Transfer Sanofi Healthcare India Private Limited acquired 3,500,000 equity shares (15.20% stake) of Sanofi India Limited from promoter entity Hoechst GmbH on 24th Sep'26. Executed via a block deal on the stock exchanges under SAST Regulation 10(1)(a)(iii), the inter-se transfer reduced Hoechst GmbH's holding from 60.38% (13,904,722 shares) to 45.18% (10,404,722 shares). Total aggregate promoter and PAC shareholding remains unchanged at 60.40% (13,909,587 shares) across an equity base of 23,030,622 shares (Rs. 230.31 mn capital).
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hoechst GmbH & PACs
Acquisition/ Disposal of Shares · 25 Sept 2026, 7:02 pm
Promoter Group Inter-Se Stake Transfer in Sanofi India Promoter entity Hoechst GmbH executed an inter-se transfer of 3,500,000 equity shares (15.20% stake) in Sanofi India Limited to Sanofi Healthcare India Private Limited via a block deal on 24th Sep'26. Following the transaction, Hoechst GmbH's holding decreased from 60.38% (13,904,722 shares) to 45.18% (10,404,722 shares), while the acquirer's holding increased to 15.20%. Total aggregate promoter and PAC shareholding in the company remains unchanged at 60.40% (13,909,587 shares).
Kindly refer the attachment
Others (Uncategorized) · 21 Sept 2026, 8:58 pm
Sanofi India Receives Order Dropping ₹1.07 Crore GST Tax Demand Sanofi India Limited received an order on 21st Sep'26 from the State Tax Officer, Tiruvallur Assessment Circle, accepting the company's submissions and dropping a total tax demand of ₹1,06,78,760 along with interest and penalty for FY'22-23. The proceedings under Section 73 of the TNGST/CGST Act, 2017—previously initiated over alleged GSTR filing anomalies—stand concluded with no additional dues pending. Consequently, the company confirmed there is no material impact on its financial or operational activities.
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Others (Uncategorized) · 18 Sept 2026, 8:05 pm
Sanofi Healthcare India to Acquire 15.20% Stake in Sanofi India via Inter-Se Transfer Sanofi Healthcare India Private Limited agreed to acquire up to 3,500,000 equity shares (15.20% stake) of Sanofi India Limited from promoter Hoechst GmbH via an inter-se promoter transfer on or after 24th Sep'26. Post-transaction, Hoechst GmbH's holding will decrease from 60.38% (13,904,722 shares) to 45.18% (10,404,722 shares), while Sanofi Healthcare India's stake will increase to 15.20%. The acquisition price will not exceed 25% over the 60-trading-day VWAMP of Rs.3,228.06 per share, qualifying for open offer exemption under Regulation 10(1)(a)(iii) of SEBI SAST Regulations.
Kindly refer the attachment
Others (Uncategorized) · 08 Sept 2026, 10:16 pm
Supreme Court Dismisses Sanofi India's Quashing Petition in CBI Procurement Case The Supreme Court of India dismissed Sanofi India's petition to quash criminal proceedings filed by the Central Bureau of Investigation regarding pharmaceutical supplies to Bhabha Atomic Research Centre, Mysore between 2012 and 2015. The ruling confirmed the maintainability of criminal prosecution against the company despite no individual employee being arraigned. The Court made no finding of guilt or merits adjudication, and the complaint remains pending trial. The judgment imposes no penalties, convictions, or operational restrictions at this stage, while Sanofi India formulates its next litigation strategy.
Kindly refer the attachment
Others (Uncategorized) · 01 Sept 2026, 2:29 am
Sanofi India Receives GST Show Cause Notice for Rs. 72.8cr Sanofi India received a Show Cause Notice on 31st Aug'26 from GST authorities regarding the misclassification of certain products for FY21. Authorities allege products were taxed at 5% instead of 12%. The notice proposes a tax liability of Rs. 36.39cr and an equivalent penalty of Rs. 36.39cr, totaling a potential financial impact of Rs. 72.78cr. The company is currently examining the notice and will respond accordingly, stating it does not currently envisage any adverse impact on its financials or operations.